Evidence map›Paper›PMID 31404589›Full record

ReviewBiochimie2019

Unfolded Protein Response supports endothelial barrier function.

Nektarios Barabutis

Open access · greenAbstract readReview
In one paragraph

Review in Biochimie, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Unfolded protein response in endothelial injury.Cell cycle (Georgetown, Tex.) · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. P53 deficiency potentiates LPS-Induced acute lung injuryCurrent research in physiology · 2020
    Article
  10. Article
  11. Review
  12. A glimpse at growth hormone-releasing hormone cosmos.Clinical and experimental pharmacology & physiology · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Autophagy, Unfolded Protein Response and Lung Disease.Current research in cell biology · 2020
    Article
  18. P53 versus inflammation: an update.Cell cycle (Georgetown, Tex.) · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nektarios BarabutisSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA, 71201, USA. Electronic address: barabutis@ulm.edu.
University of Louisiana at Monroe · US

Funding

STABILITY' (symptomatic review during biologic therapy) Review in Inflammatory Bowel DiseaseP20GM103424 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI Seetharama D Jois · 2012 to 2026
$57.4M
NIGMS NIH HHS P20 GM103424
6 · The paper itself

Abstract

Ongoing efforts are oriented towards the development of novel therapeutic agents to repress lung hyperpermeability responses due to inflammation. The endothelial barrier dysfunction triggered by such events, may eventually lead to severe cardiovascular complications, such as the Acute Respiratory Distress Syndrome. Hsp90 inhibitors are anticancer compounds, associated with strong anti-inflammatory responses in the endothelium. Our latest observations in experimental models of Acute Lung Injury suggest that P53 orchestrates, at least in part, such activities. Remarkably, both Hsp90 inhibition and P53 induction are associated with the activation of the Unfolded Protein Response element. The purpose of the current manuscript, is to introduce the hypotheses that UPR induction protects the vasculature against inflammation.

Indexed as

Acute Lung InjuryRespiratory Distress SyndromeAnimalsCapillary PermeabilityCells, CulturedEndothelium, VascularHSP90 Heat-Shock ProteinsHumansInflammationMiceTumor Suppressor Protein p53Unfolded Protein ResponseHSP90 Heat-Shock ProteinsTumor Suppressor Protein p53

Identifiers

PMID31404589
PMCPMC6746596
OpenAlexW2968902323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.